Electronic prescribing: ready for prime time?
Escalating drug expenditures and the prevalence of medication errors have prompted calls for drug cost control and quality improvement. E-prescribing promises to address these concerns. This study aims to describe the benefits and costs of eRx as assessed by key industry stakeholders, identify the components of a needed electronic prescribing infrastructure and the barriers to its completion, and identify potential public and private policies and initiatives that could encourage the development of an EPI and hasten eRx adoption among stakeholders.
Lipton
Helene Levens
HL
Department of Clinical Pharmacy and Institute for Health Policy Studies, Schools of Pharmacy and Medicine, University of California at San Francisco, USA.
Miller
Robert H
RH
Wimbush
Julian J
JJ
D016303:Clinical Pharmacy Information Systems; D004059:Diffusion of Innovation; D016527:Drug Costs; D011307:Drug Prescriptions; D006801:Humans; D007449:Investments; D016347:Medical Records Systems, Computerized; D017149:Private Sector; D017150:Public Sector; D014481:United States